GENET-news
To stay informed you can subscribe to the GENET-news list.
2008-12-09 | permalink
SemBioSys begins phase I/II trial of insulin produced in GE pharma plant seeds
SemBioSys Genetics Inc., a biotechnology company developing protein pharmaceuticals in crop plants, today announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers.
Overview
News
2008-12-09 | permalink
SemBioSys begins phase I/II trial of insulin produced in GE pharma plant seeds
SemBioSys Genetics Inc., a biotechnology company developing protein pharmaceuticals in crop plants, today announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers.
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.